# Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

> **NCT00699166** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 135 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** DNK333

## Key facts

- **NCT ID:** NCT00699166
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2008-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699166, "Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00699166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*